Recombinant Proteins Market

The recombinant proteins market is projected to reach USD 3.90 billion by 2031 from USD 2.63 billion in 2026, at a CAGR of 8.2% during the forecast period. The recombinant proteins market is driven by the growing pipeline of recombinant therapeutics, increasing demand for biologics and vaccines, and expanding applications in drug discovery, diagnostics, and cell and gene therapy. Advances in protein engineering, mammalian expression systems, and manufacturing technologies are improving protein yield, stability, and biological activity, while rising investments in biopharmaceutical research are creating further growth opportunities.

Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), Bio-Techne (US), Danaher Corporation (US), and Revvity (US) are the key players in this market.
These market players have adopted various strategies, including portfolio expansion, investments in protein expression technologies, development of specialized recombinant proteins, and enhancements to biopharmaceutical manufacturing capabilities. In September 2025, Merck KGaA introduced its CHOZN Elite cell line, a next-generation Chinese hamster ovary (CHO) expression system designed to improve recombinant protein production through higher-producing clones and increased protein titers. The launch strengthened Merck’s capabilities in mammalian expression technologies for biopharmaceutical manufacturing.

To know about the assumptions considered for the study download the pdf brochure

In May 2026, Miltenyi Biotec launched research-grade recombinant human IL-18, a pro-inflammatory cytokine optimized for cell-culture and functional-assay applications. The product supports NK-cell expansion and activation, cytokine-induced memory-like NK-cell generation, CAR-T research, and investigation of IL-18-mediated signaling pathways.

Thermo Fisher Scientific Inc. (US): Thermo Fisher offers an extensive recombinant protein portfolio through its Gibco, Invitrogen, and PeproTech brands, covering cytokines, growth factors, and other proteins for research, drug discovery, and biopharmaceutical applications. Its PeproGMP portfolio includes GMP-grade recombinant cytokines and growth factors designed to support cell therapy manufacturing. These proteins are produced using defined, animal-origin-free materials and are supported by quality controls and manufacturing documentation. The company’s portfolio supports cell expansion, differentiation, and activation across stem cell, immune cell, and organoid workflows, strengthening its position across research and clinical manufacturing applications.

Merck KGaA (Germany): Merck provides recombinant protein production technologies and cell-line development solutions through its Life Science business. In September 2025, the company launched its CHOZN Elite cell line, which uses suspension-adapted CHO cells and chemically defined, animal-component-free media to support high-producing clones and improve protein titers. The system is designed to enhance productivity and manufacturing efficiency for monoclonal antibodies and other recombinant proteins. This development strengthens Merck’s position in mammalian expression systems and supports biopharmaceutical manufacturers seeking scalable and consistent protein production.

Bio-Techne (US): Bio-Techne offers an extensive portfolio of recombinant proteins through its R&D Systems brand, including cytokines, growth factors, chemokines, and other biologically active proteins for cell culture, immunology, cancer research, and drug discovery. Its portfolio includes research-use-only, animal-free, and GMP-grade proteins, supporting applications from basic research to therapeutic development. In January 2025, the company expanded its AI-engineered designer protein portfolio with heat-stable and hyperactive proteins, including IL-2 Heat Stable Agonist, Activin A Hyperactive, and FGF basic Heat Stable, designed to improve protein activity and performance in cell culture and cell therapy workflows.

Market Ranking

The recombinant proteins market is competitive, with leading suppliers differentiating through portfolio breadth, protein purity, biological activity, expression-system capabilities, and specialized formulations for research and biopharmaceutical applications. Key players include Thermo Fisher Scientific Inc. (US), Merck KGaA (Germany), and Bio-Techne (US). Thermo Fisher Scientific offers recombinant cytokines, growth factors, chemokines, enzymes, and receptors through its Gibco, Invitrogen, and PeproTech brands, supporting drug discovery, cell culture, immunology, and cell therapy research. Bio-Techne strengthens its position through R&D Systems recombinant proteins, including cytokines, growth factors, and engineered proteins designed to improve biological activity and stability. Merck KGaA contributes through its Sigma-Aldrich and MilliporeSigma portfolios of recombinant cytokines, growth factors, kinases, enzymes, hormones, and receptors, alongside protein expression and bioprocessing technologies that support research and manufacturing workflows. Collectively, these companies support demand across pharmaceutical and biotechnology companies, contract research organizations, and academic and research institutes by providing recombinant proteins for drug discovery and development, research, diagnostics, and biopharmaceutical production.

Related Reports:

Recombinant Proteins Market by Product (Growth Factors, Chemokines, Membrane Proteins, Receptors), Host Cell (Mammalian, Insect, Yeast), Application (Drug Discovery, Development [Biologics, CGT, Vaccines], Research, Production)- Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]